InvestorsHub Logo
Followers 3
Posts 300
Boards Moderated 0
Alias Born 12/21/2022

Re: None

Sunday, 05/28/2023 9:08:46 AM

Sunday, May 28, 2023 9:08:46 AM

Post# of 581
Japan's Ministry of Health, Labour, and Welfare has approved quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation and as maintenance monotherapy in patients with newly diagnosed acute myeloid leukemia whose tumors harbor FLT3-ITD mutations. It can be approved by FDA in same indications by Jul 24, 2023. This approval certainly will affect a design of Tusp registrational study. Big uncertainty is that we don't know whether Tusp works after Quiz in Flt3 mut patients or not.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News